The $50M ATM represents massive dilution potential (85% of current market cap) and will likely be drawn down to repay the Yorkville note and fund operations. Monitor daily volume and ATM sales disclosures. The company must also resolve its Nasdaq deficiency by August 24, 2026 — failure could accelerate distress. Short-term trading will be dominated by ATM mechanics and potential price pressure.
Price Chart
Executive Summary
PDS Biotechnology closed a $6M promissory note financing with Yorkville affiliate YA II PN, Ltd. (10% interest, 12-month maturity) and entered into a $50M at-the-market (ATM) equity offering program with Yorkville Securities and B. Riley Securities. The company also repaid its existing JGB debentures at a 103% premium. The ATM, which is 85% of current market cap, creates massive dilution risk and proceeds are required to first repay the Yorkville note.
Key Financial Metrics
Key Facts
- Closed $6M promissory note with YA II PN, Ltd. at 96% of face value ($5.76M net), 10% interest, 12-month maturity
- Issued warrant to purchase 2,158,274 shares at $1.1824 per share (out of the money vs. ~$1.06 current price)
- Entered into $50M at-the-market (ATM) sales agreement with Yorkville Securities and B. Riley Securities
- Repaid and terminated existing JGB Senior Secured Convertible Debentures at 103% of principal plus accrued interest
- ATM proceeds must first be applied to amortization payments under the promissory note before working capital use
- Company has a Nasdaq deficiency letter (Feb 25, 2026) that must be resolved by August 24, 2026
Financial Impact
Up to $50M in potential equity dilution via ATM on a $59M market cap; $6M promissory note at 10% interest; warrant adds 2.16M shares of overhang
Risk Factors
- Massive dilution from $50M ATM relative to $59M market cap
- High-cost debt (10% interest) with 12-month maturity creates refinancing risk
- Warrant overhang (2.16M shares) adds further dilution when exercised
- Nasdaq deficiency letter unresolved — delisting risk if not cured by August 24, 2026
- Yorkville affiliate involvement raises conflict-of-interest concerns (lender, ATM agent, warrant holder)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-025207 |
| Document: ef20076071_ex10-1.htm | 0001140361-26-025207 |
| Document: ef20076071_8k.htm | 0001140361-26-025207 |
| Document: ef20076071_ex5-1.htm | 0001140361-26-025207 |
| Document: 0001140361-26-025207-index-headers.html | 0001140361-26-025207 |
| Document: 0001140361-26-025207-index.html | 0001140361-26-025207 |
| Document: 0001140361-26-025207.txt | 0001140361-26-025207 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | 8-K | $0.3000 $0.5853 | ▼ −95.10% | ▼ −96.22% | $0.7366 (−145.53%) |
Aug 19, 2026 6w ago | 8-K | $0.2089 $0.2179 | ▲ +4.31% | ▲ +3.19% | $0.7366 (+252.61%) |
Aug 13, 2026 7w ago | 8-K | $0.2332 $0.2089 | ▲ +10.42% | ▲ +8.46% | $0.7366 (−215.87%) |
Aug 11, 2026 7w ago | 8-K | $0.2570 $0.2080 | ▲ +19.07% | ▲ +18.66% | $0.7366 (−186.61%) |
Jul 22, 2026 10w ago | EFFECT | $0.7155 $0.6696 | ▲ +6.42% | ▲ +4.01% | $0.7366 (−2.95%) |
Jun 26, 2026 13w ago | DEFA14A | $0.8991 $0.8461 | ▼ −5.89% | ▼ −7.28% | $0.7366 (−18.07%) |
Jun 15, 2026 15w ago | 8-K | $0.9600 $0.9120 | ▲ +5.00% | ▲ +2.77% | $0.7366 (+23.27%) |
Jun 15, 2026 15w ago | 8-K | $1.02 $0.9412 | ▼ −7.73% | ▼ −6.34% | $0.7366 (−27.78%) |
Jun 2, 2026 17w ago | 8-K | $1.16 $1.03 | ▼ −11.21% | ▼ −8.24% | $0.7366 (−36.50%) |
May 13, 2026 20w ago | Press Release | $1.33 $1.00 | ▼ −24.81% | ▼ −23.65% | $0.7366 (−44.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access